Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 22;14(7):1605.
doi: 10.3390/cancers14071605.

Divergent Patterns in Care Utilization and Financial Distress between Patients with Blood Cancers and Solid Tumors: A National Health Interview Survey Study, 2014-2020

Affiliations

Divergent Patterns in Care Utilization and Financial Distress between Patients with Blood Cancers and Solid Tumors: A National Health Interview Survey Study, 2014-2020

Christopher T Su et al. Cancers (Basel). .

Abstract

Introduction: Important differences exist between the presentation, treatment, and survivorship of patients and survivors with blood cancers. Furthermore, existing research in financial toxicity has not fully addressed the relationship between medical care utilization and patient-reported outcomes of financial barriers and distress. We answered these questions by using a nationally representative survey. Methods: Respondents with blood cancers and solid tumors from the National Health Interview Survey were identified (2014−2020). We identified 23 survey questions as study outcomes and grouped them into three domains of medical care utilization, financial barriers to care, and financial distress. Associations between the three domains and associations of study outcomes between cancer types were examined using weighted univariate analyses and multivariable linear and logistic regressions. Results: The final study group consisted of 6248 respondents with solid tumors and 398 with blood cancers (diagnosed ≤ 5 years). Across all respondents with cancer, higher medical care utilization is generally associated with increased financial barriers to care. Compared to respondents with solid tumors, respondents with blood cancers had a higher level of medical care utilization (β = 0.36, p = 0.02), a lower level of financial barriers to care (β = −0.19, p < 0.0001), and a higher level of financial distress in affording care (β = 0.64, p = 0.03). Conclusions: Patients and survivors with blood cancers and solid tumors demonstrate divergent patterns in care utilization, financial barriers, and financial distress. Future research and interventions on financial toxicity should be tailored for individual cancer groups, recognizing the differences in medical care utilization, which affect the experienced financial barriers.

Keywords: financial hardship; financial stress; health services accessibility; health services research; healthcare surveys; hematologic neoplasms; medical oncology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
NHIS cohort identification.
Figure 2
Figure 2
Multivariable analyses of association between medical care utilization (represented by receiving care 10+ times in 12 months) and study outcomes in the domains of financial barriers to care and financial distress of affording care.

Similar articles

Cited by

References

    1. Carrera P.M., Kantarjian H.M., Blinder V.S. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J. Clin. 2018;68:153–165. doi: 10.3322/caac.21443. - DOI - PMC - PubMed
    1. Narang A.K., Nicholas L.H. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer. JAMA Oncol. 2017;3:757–765. doi: 10.1001/jamaoncol.2016.4865. - DOI - PMC - PubMed
    1. Smith G.L., Lopez-Olivo M.A., Advani P.G., Ning M.S., Geng Y., Giordano S.H., Volk R.J. Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes. J. Natl. Compr. Cancer Netw. 2019;17:1184–1192. doi: 10.6004/jnccn.2019.7305. - DOI - PMC - PubMed
    1. De Souza J.A., Yap B.J., Wroblewski K., Blinder V., Araújo F.S., Hlubocky F.J., Nicholas L.H., O’Connor J.M., Brockstein B., Ratain M.J., et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) Cancer. 2017;123:476–484. doi: 10.1002/cncr.30369. - DOI - PMC - PubMed
    1. Zafar S.Y., Peppercorn J.M., Schrag D., Taylor D.H., Goetzinger A.M., Zhong X., Abernethy A.P. The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18:381–390. doi: 10.1634/theoncologist.2012-0279. - DOI - PMC - PubMed

LinkOut - more resources